CEL-SCI Corporation 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for CEL-SCI Corporation for the period ended December 31, 2009. The Company is a biotechnology firm focused on the development of Multikine (for cancer treatment) and L.E.A.P.S. technology. It is classified as a smaller reporting company and a non-shell company. As of February 1, 2010, there were 204,201,968 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2010 (Ended Dec 31, 2009) | Q1 2009 (Ended Dec 31, 2008) |
|---|---|---|
| Total Revenue | $30,000 | $0 |
| Net Income (Loss) | $19,159,517 | $(2,173,513) |
| Operating Loss | $(4,252,849) | $(2,551,823) |
| Research & Development Expenses | $2,805,127 | $1,410,753 |
| Cash and Cash Equivalents | $36,040,879 | $98,947 (End of Period) |
| Derivative Liabilities | $12,912,022 | $35,113,970 (Prior Quarter) |
| Net Cash Used in Operating Activities | $(3,623,098) | $(1,091,486) |
| Net Cash Provided by Financing Activities | $6,157,450 | $114,922 |
Material Changes vs. Prior Period
- Net Income Surge: The Company reported a net income of $19.16 million, a reversal from a $2.17 million loss in the prior year. This is primarily driven by a non-cash gain on derivative instruments of $23.34 million, resulting from the revaluation of warrants and a decline in the Company's stock price.
- Operating Performance: Core operations remain unprofitable. Operating loss widened to $4.25 million from $2.55 million due to a 99% increase in R&D expenses ($2.81 million vs. $1.41 million) as the Company prepares for Phase III clinical trials.
- Liquidity Improvement: Cash and cash equivalents increased by $2.47 million to $36.04 million, driven by $6.16 million in proceeds from the exercise of stock options and warrants.
- Derivative Liability Reduction: Derivative liabilities decreased significantly from $35.11 million (Sept 30, 2009) to $12.91 million (Dec 31, 2009) due to warrant exercises and fair value adjustments.
Outlook, Risks, and Management Commentary
- Clinical Trial Progress: The Company is preparing for the Phase III clinical trial for Multikine in head and neck cancer. The estimated net cost for this trial is $20 million. Two partners have agreed to fund a portion of this trial.
- Liquidity Position: Management believes current funds are sufficient to support operations for more than the next twelve months. The Company has a $5 million Equity Line of Credit available but has not drawn on it during the quarter.
- Revenue Uncertainty: The Company has not generated revenue from product sales. Future revenue depends on completing clinical trials, obtaining FDA approval, and commercializing products, which is uncertain.
- Lease Contingency: The Company leases a 73,000 sq. ft. manufacturing facility. While previously in non-compliance regarding rent payments, the lease was renegotiated, and the Company is now in compliance. A deposit of $1.575 million is expected to be refunded.
- Accounting Changes: Effective October 1, 2009, certain warrants were reclassified from equity to derivative liabilities due to new accounting standards (Codification 815-40), impacting the balance sheet and earnings through mark-to-market adjustments.
Investor Verification Checklist
- Non-Cash Earnings: Verify that the $19.16 million net income is almost entirely non-cash (driven by derivative gains) and does not reflect operational profitability.
- Cash Burn Rate: Confirm the sustainability of the $3.62 million quarterly cash burn from operations against the $36 million cash balance.
- Phase III Funding: Assess the certainty of the $20 million funding requirement for the Multikine Phase III trial and the commitment levels of the two partners.
- Derivative Volatility: Monitor the fair value of remaining derivative liabilities ($12.9 million), as future stock price fluctuations will continue to create significant volatility in reported earnings.
- Regulatory Status: Track the timeline for FDA approval of the Phase III protocol and any potential delays in clinical trial initiation.